An enlarged fetal thyroid in a Graves pregnancy is a finding—not a verdict. It can develop when maternal antibodies stimulate the fetal thyroid, or when antithyroid medication suppresses fetal hormone production. Changing treatment based on gland size alone could push the fetus further in the wrong direction.
Illustrative case: At 26 weeks, a patient with Graves disease has markedly elevated thyroid-stimulating hormone receptor antibodies (TRAb) and a reported fetal heart-rate baseline of 175 beats per minute. A later ultrasound identifies fetal thyroid enlargement. Surveillance is warranted; the harder question is what is driving the goiter—and whether the evidence is strong enough to change treatment.
Two opposing mechanisms can enlarge the same gland
Maternal TRAb cross the placenta and can stimulate the fetal thyroid, causing fetal hyperthyroidism and sometimes goiter. Antithyroid drugs (ATDs) also cross the placenta. If their effect suppresses fetal hormone production, the fetal pituitary may respond with increased thyroid-stimulating hormone, which can enlarge the fetal gland even as the fetus becomes hypothyroid.
That means a goiter can occur in two physiologically opposite states. In this case, high TRAb raises concern for fetal hyperthyroidism. If an ATD is being used or resumed, its placental passage creates a separate risk of fetal hypothyroidism if the dose suppresses fetal thyroid function. Less commonly, iodine exposure or an intrinsic fetal thyroid hormone-production disorder may be relevant.
Maternal results still matter, but they do not settle fetal thyroid status by themselves. The 2026 American Thyroid Association (ATA) guidance recommends monitoring for fetal and neonatal hyperthyroidism when TRAb or thyroid-stimulating immunoglobulin (TSI) is more than three times the assay’s upper limit of normal. In this illustration, the reported TRAb of 50 U/L with a laboratory upper limit of 1.75 U/L is about 29 times the upper limit. That supports surveillance; it does not prove the fetus is hyperthyroid.
Read the ultrasound as a pattern, not a single sign
A fetal goiter, or thyroid volume above the expected range for gestational age, cannot distinguish hyperthyroidism from hypothyroidism. Look at the surrounding findings and how they change over time.
| Finding | May support | Important limit |
|---|---|---|
| Persistent fetal tachycardia | Fetal hyperthyroidism | Confirm persistence and interpret the tracing in context; it is not a diagnosis by itself. |
| Central or diffuse thyroid vascularity on Doppler | Fetal hyperthyroidism | Supportive, not definitive; evidence comes from limited observational data. |
| Peripheral thyroid vascularity or delayed bone maturation | Fetal hypothyroidism | Neither finding alone establishes fetal thyroid function. |
| Advanced bone maturation, growth restriction, cardiomegaly, or hydrops | Fetal hyperthyroidism | These findings have different degrees of specificity and may have other explanations. |
| Polyhydramnios, neck extension, or difficulty swallowing | A large goiter affecting swallowing or neck position | These are important mechanical findings but do not identify the thyroid’s hormone state. |
Doppler vascularity and bone maturation can help refine the differential, but they are clues—not stand-alone tests. A small retrospective ultrasound study proposed combining vascularity, fetal heart rate, bone maturation, and fetal movement to predict fetal thyroid function. The approach is useful for organizing observations, but it does not make any one feature a definitive diagnostic criterion.
The reported heart-rate baseline of 175 beats per minute deserves attention, but avoid translating one tracing finding directly into fetal Graves disease. Review whether tachycardia is persistent, assess the maternal clinical picture and medications, and evaluate the complete ultrasound pattern. The same caution applies in reverse: a reassuring maternal thyroid result does not rule out fetal effects when TRAb remains high or ATDs are being used.
Before adjusting medication, close the information gaps
First, review the mother’s current symptoms, medication history and adherence, dose, and thyroid-function results using pregnancy- and assay-appropriate reference ranges. Current ATA guidance targets a maternal free T4 concentration at or slightly above the upper third of the reference interval during ATD treatment. The goal is not simply to drive maternal results as low as possible; excessive suppression can expose the fetus to hypothyroidism.
Next, ensure fetal assessment is sufficiently detailed. ATA guidance recommends monthly fetal ultrasound from 18–20 weeks when TRAb or TSI remains above three times the upper limit of normal; fetal thyroid ultrasound monitoring is also recommended for patients using ATDs. Depending on the case, follow-up should consider thyroid size and vascularity, heart rate, growth, bone maturation, amniotic fluid, cardiac findings, and the goiter’s effect on swallowing or the airway.
Then match the medication decision to the combined evidence. If findings support fetal hyperthyroidism, maternal ATD therapy may treat the fetal condition as well as the mother’s Graves disease. If fetal hypothyroidism from medication is more likely, the treating team may need to reduce or otherwise adjust the ATD while maintaining appropriate maternal control. Either way, a goiter alone is not a reason to increase or stop medication. Coordinate decisions with maternal-fetal medicine and clinicians experienced in thyroid disease in pregnancy. In selected cases with unresolved, management-changing uncertainty, fetal testing may be discussed; invasive sampling is not a routine response to every goiter.
Plan for the goiter’s mechanical effects and the newborn
Thyroid function is not the only concern. A large fetal goiter can impair swallowing, contribute to polyhydramnios, alter neck position, or create airway considerations for the newborn. Document these features and involve the appropriate neonatal team when the size or location raises concern. Evidence on delivery mode is limited and case-based; a fetal goiter alone does not automatically dictate cesarean birth. Plan route and timing around the full obstetric picture, especially if mechanical obstruction is suspected, with airway planning as appropriate.
A clear handoff matters after delivery, too. When maternal TRAb is substantially elevated, plan neonatal thyroid follow-up with the pediatric team. If the mother is taking an ATD, the newborn may initially appear euthyroid and develop thyrotoxicosis as the medication’s effect fades while maternal antibodies remain active.
Common traps to avoid
- Calling every fetal goiter hyperthyroidism: Both antibody stimulation and medication-related suppression can enlarge the gland.
- Letting a high TRAb titer answer the whole question: It raises risk and supports surveillance, but does not prove current fetal thyroid function.
- Treating Doppler or bone age as definitive: These are supportive findings that must be interpreted together.
- Adjusting medication from gland size alone: Check maternal status, drug exposure, and the broader fetal pattern first.
Practical takeaways
- Fetal goiter in Graves pregnancy can reflect either hyperthyroidism or hypothyroidism.
- Interpret TRAb, ATD exposure, maternal thyroid function, and fetal ultrasound together.
- Use fetal heart rate, Doppler, bone maturation, growth, amniotic fluid, and cardiac findings as a pattern—not isolated verdicts.
- Do not change ATD therapy solely because the fetal thyroid is enlarged; coordinate a plan that protects both maternal and fetal thyroid function.
- Consider the goiter’s mechanical effects and ensure neonatal thyroid follow-up is part of the delivery plan.
